Loading
A drug's label should say plainly how well the people in its trials matched the people who get the disease: 'Black patients were 4 percent of participants and 22 percent of cases.' Doctors and patients can then judge how far to trust the result.
Labels and public assessment reports (FDA, EMA EPAR) include a standard representativeness panel: enrolled percentages by race, ethnicity, sex, age band and region beside incidence-based expected percentages, with a participation-to-prevalence ratio per stratum. The panel is machine-readable and aggregated in a public dashboard.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Trials do not represent the people who get cancer.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.